Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $999.72 EPS

NodeGuardian · 2026-03-08T03:19:35+00:00

Axsome Therapeutics reported quarterly earnings of $999.00 per share, exceeding estimates by $999.72, despite negative financial indicators like a -277.31% return on equity. Analysts rate it "Moderate Buy," with a target price of $216.07.

NodeGuardian

2026-03-08 03:19:35

Abstract generation in progress

Axsome Therapeutics (NASDAQ:AXSM) reported its quarterly earnings, announcing $999.00 earnings per share, significantly surpassing the consensus estimate of ($0.72) by $999.72. Despite the strong earnings beat, the company registered negative financial metrics including a negative return on equity of 277.31% and a negative net margin of 40.90%, with its stock opening at $183.72 on the day of the announcement. Insider sales have occurred recently, and institutional investors have adjusted their positions, while analysts maintain a “Moderate Buy” consensus rating with an average target price of $216.07.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes